TB-500: adverse events and evidence limits
The public TB-500 description calls it an active thymosin beta4 fragment; the specification also uses the name Thymosin Beta-4. That alias does not prove the product is intact 43-residue beta4. The inspected fields do not establish the exact fragment sequence or terminal modifications [1].
The inspected primary abstract concerns G-actin binding by beta4 variants and the effects of their modifications. It neither identifies the sold material nor provides its clinical reaction frequency [2].
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Clinical reaction frequency for the product | The inspected primary abstract concerns G-actin binding by thymosin β4 variants (biochemistry); the product’s exact fragment sequence is not established | The abstract neither identifies the sold material nor provides its clinical reaction frequency | [1][2] |
References
- Longeva (2026). TB-500 https://longeva.bio/en/product/tb-500.
- Zoubek RE; Hannappel E (2007). Influence of the N terminus and the actin-binding motif of thymosin beta4 on its interaction with G-actin. https://pubmed.ncbi.nlm.nih.gov/17495251/ doi:10.1196/annals.1415.026.